Billionaire founder of opioid firm guilty of bribing

New Post Public Reply Private Reply Replies (0) Message Board
jrt03
278
Billionaire founder of opioid firm guilty of bribing doctors to prescribe drug

Chris McGreal
First published on Thu 2 May 2019 15.04 EDT
John Kapoor, 75, also guilty of defrauding insurance companies
Prosecutors say fentanyl drug Subsys fuelled opioid epidemic
John Kapoor, right, over saw Insys’s marketing strategy of hiring doctors as seminar speakers as cover to pay them more than $1m to prescribe high doses of Subsys.
The head of a leading drug manufacturer has been found guilty of bribing doctors to prescribe a dangerous painkiller to patients who did not need it in the first criminal conviction of a pharma chief over the opioid epidemic.

A Boston jury also found John Kapoor, the 75-year-old billionaire founder of Insys Theraputics, guilty of defrauding insurance companies in the push to sell Subsys, a spray made from fentanyl, a synthetic opioid many times stronger than morphine.

Subsys was approved for terminal cancer patients but the company targeted sales at a much bigger and more profitable market of people with non-life threatening chronic pain. Prosecutors said that fuelled the opioid epidemic and cost lives.

Four other Insys executives were also convicted on similar racketeering charges after the jury took two weeks to deliberate. They each face up to 20 years in prison.

The convictions will spur demands for executives of other opioid makers to be held to account for an epidemic that has claimed about 400,000 lives over the past two decades.

Drug manufacturers, distributors and pharmacies are already facing hundreds of civil lawsuits by states and cities seeking to recover the costs of the epidemic on public finances, from increased crime to addiction treatment and care for orphaned children. On Thursday, the drug distributor, McKesson, agreed to pay West Virginia $37m to settle a lawsuit over flooding the state with millions of opioid pills without abiding by proper controls.

But there is mounting anger that corporations have spent years paying civil settlements as “the cost of doing business” while continuing to rake in huge profits by illegally pushing the mass prescribing of the drugs or failing to obey laws intended to prevent their misuse. Political leaders in some of the worst-hit parts of the country have called for criminal prosecutions of the executives who made the decisions calling them “drug dealers in Armani suits”.

Kapoor oversaw a marketing strategy at Insys that hired doctors as speakers at educational seminars as cover to pay them more than $1m to prescribe high doses of Subsys to patients who did not need it. Prosecutors said the seminars were no more than social gatherings at expensive New York restaurants followed by company sales reps taking the physicians to strip clubs and bars.

Prosecutors showed the jury spreadsheets of payments to doctors and how much the company profited from each bribe. In one instance, the company paid nearly $260,000 to two New York doctors who wrote more than $6m worth of Subsys prescriptions in 2014. Insys employees also posed as doctors to give insurance companies invented diagnoses to get approval for payments for the drug.

The jury was also shown a promotional rap video of Insys sales reps dancing next to a large bottle of Subsys including the line, “I got new patients, and I got a lot of ’em.”

Sales of Subsys surged as a result of the company’s aggressive marketing, rising from $14m in 2012 when the drug came on the market to nearly half a billion dollars five years later. Fentanyl is a powerful and highly addictive drug that has killed more people than any other opioid over recent years, although most of those who overdose do so on illegal versions of the drug smuggled into the country.

Prosecutors said the kickback scheme was one factor in the opioid epidemic as doctors “saw a huge payday that potentially put people’s lives in danger”. They showed the jury emails in which a former Insys CEO said certain doctors were “owned” by the company because of the amount of Subsys they prescribed.

Prosecutors said the Insys executives risked the lives of patients out of greed.

“These patients were used. Their pain was exploited,” US attorney Nathaniel Yeager told the jury. “The decisions, the money, the strategy came from the top.”

The company’s former vice-president of managed markets, Michael Gurry; its former national sales director, Richard Simon; and two sales directors, Sunrise Lee and Joseph Rowan, were also convicted.

Several other former Insys executives previously pleaded guilty over the scheme and gave evidence against Kapoor.

Michael Babich, the former Insys CEO, pleaded guilty earlier this year. Babich faces up to 20 years in prison when he is sentenced later this year. Babich’s wife, Natalie Levine, an Insys sales rep, is also awaiting sentencing after pleading guilty over the kickback scheme.

Others convicted include the company’s vice-president of sales, Alec Burlakoff, who told the trial Kapoor devised a sales strategy to target doctors known to dispense opioids without too many questions in so-called “pill mills”.

“Pill mills, for us, meant dollars,” he said.

Since you’re here…

… we have a small favour to ask. More people are reading and supporting our independent, investigative reporting than ever before. And unlike many news organisations, we have chosen an approach that allows us to keep our journalism accessible to all, regardless of where they live or what they can afford.

The Guardian is editorially independent, meaning we set our own agenda. Our journalism is free from commercial bias and not influenced by billionaire owners, politicians or shareholders. No one edits our editor. No one steers our opinion. This is important as it enables us to give a voice to those less heard, challenge the powerful and hold them to account. It’s what makes us different to so many others in the media, at a time when factual, honest reporting is critical.

Every contribution we receive from readers like you, big or small, goes directly into funding our journalism. This support enables us to keep working as we do – but we must maintain and build on it for every year to come. Support The Guardian from as little as $1 – and it only takes a minute. Thank you.

https://www.theguardian.com/us-news/2019/may/...-prescribe

Time for Univec... Dr Dalton has a plan! UNVC!

Univec Conglomerate Inc (UNVC) Stock Research Links

UNVC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating Hit and Run Protocols in St. Tammany Parish

Updated Category News Views 2

When the Driver Disappears: Steps Forward Hit and run accidents can leave you feeling abandoned and unsure of what to do. In St. Tammany Parish, this scenario is all too familiar. Personal Injury Attorney Ross F. Lagarde cuts through the chaos, offering a clear path for those caught in this nightmare, explained in HelloNation's comprehensive guide. Prioritize Safety and...

Continue Reading
GoLive Streamers: A Social Media Wild Card

Updated Category News Views 6

Stepping Boldly into the Livestreaming Arena There's a new kid in the chaotic neighborhood of social media, and it's called GoLive Streamers. Not just another aimless stroll down Content Highway, GoLive is weaving its own defining path by fostering genuine real-time interaction. Launched in April 2026, this plucky platform has quickly amassed a following of over 74,000...

Continue Reading
Hi-Tech's Dubai Chocolate Adds Flavor to Sales Surge

Updated Category News Views 4

Ever found a protein shake that tastes like a candy bar from the future? Well, Hi-Tech Pharmaceuticals is banking on their new Dubai Chocolate flavor to hit that sweet spot. This isn't your typical powdered shake game; Hi-Tech's been cranking the flavor dial ever since they introduced their Precision Protein® line back in 2016. They've carved out a niche with unique...

Continue Reading
Decision Logic Innovates with Vitals & ShiftFlow Tools

Updated Category News Views 2

Restaurant Battlefields: The Need for Real-Time Response Running a restaurant is no walk in the park. One slip, and you're dealing with spoiled soup or crabby customers. Decision Logic reckons they've cracked the code to smoother operations with their new tools, Vitals and ShiftFlow. At heart, these products do one thing: put critical data into the hands of managers while...

Continue Reading
SACHEU Partners with AI to Harness Real Customer Insights

Updated Category News Views 4

Rethinking Beauty Industry's AI Obsession Here’s a breath of fresh air from the otherwise AI-obsessed beauty landscape: SACHEU, the brand that's been turning heads in cosmetics, decided to pair up with Limitless Labs. This partnership isn't about ceding control to machines but amplifying genuine human voices in their product development process. Yeah, it's a...

Continue Reading
Flux Expands AI Platform to Prove Engineering ROI

Updated Category News Views 6

Navigating the AI Maze: Flux's New Pathways Ever feel like these engineering platforms speak a language of their own? Flux's latest expansion finally offers a translator that matters. It's all about decoding whether your AI investment is delivering the goods. Engineering leaders now have more than just fluffy metrics; Flux breaks down real code-based evidence to show if...

Continue Reading
Riverside Theatre Appoints Seasoned CFO for Growth Phase

Updated Category News Views 6

Change Is Afoot at Riverside Theatre Down in Vero Beach, amid the sun-drenched coziness of Florida’s Treasure Coast, something’s cooking that has nothing to do with sunshine: Riverside Theatre snagged itself a new Chief Financial Officer. As nonprofits go, this one’s not a backyard operation—it’s the largest independent professional theatre in the entire state....

Continue Reading
Synopsys-TSMC Collaboration Drives AI System Evolution

Updated Category News Views 3

Synopsys and TSMC: The New Power Couple in AI Ah, the world of semiconductors—where the chips are small but the stakes are colossal. Once again, Synopsys and TSMC have thrown their hats into the ring, diving headfirst into yet another ambitious collaboration. Their latest mission? To fast-track the evolution of AI systems through a suite of innovations strapped to...

Continue Reading
First Lady Steals NYSE Show, Investors Eye Stakes

Updated Category News Views 3

Something's Buzzing at the Big Board Walk over to Wall Street on September 23rd, and guess what you get? A lot more than just stock tickers blinking away. First Lady Melania Trump’s stealing the show at the New York Stock Exchange to kick off the inaugural IMPERIA Summit. She’s there to sound the opening bell and lead the charge in a summit that's focused on the...

Continue Reading
Apex Dental's Growth Shines in Inc. 5000 Ranking

Updated Category News Views 4

Another Year, Another Milestone for Apex Dental Let's talk about steady growth. Apex Dental Partners has made it onto the Inc. 5000 list for the eighth straight year, landing at No. 3,850. Quite a feat, considering this list only features America's fastest-growing private companies. Apex isn't just maintaining its position out of sheer luck. Revenue shot up by 67% over...

Continue Reading

Top 5 Most Recently Viewed Articles

Grayscale Investments Unveils Innovative XRP Trust for Investors

Updated Category News Views 73

Grayscale Investments Launches Grayscale XRP Trust Grayscale Investments, a well-known asset management firm specializing in digital currencies, is excited to announce the public launch of its Grayscale XRP Trust. This new offering provides a unique opportunity for investors to gain exposure to XRP, the cryptocurrency underpinning the XRP Ledger (XRPL). The XRPL is a...

Continue Reading
Citi Maintains Neutral Outlook on Nasdaq Shares with Growth Potential

Updated Category News Views 61

So, Citi kept its Neutral rating on Nasdaq Inc. back in 2024, setting a price target of $70. You know how it goes—when you chat with company brass like President Tal Cohen, sometimes it sways analysts' thoughts. That meeting kicked up some optimism about Nasdaq’s growth path—sure, they threw around terms like 'structural catalysts' and 'cross-selling opportunities'....

Continue Reading
Discover Luxury Living at The Diamond Exchange Building

Updated Category News Views 193

Discover the Unique Charm of The Diamond Exchange Building The former Diamond Exchange located at 14 Maiden Lane has undergone a magnificent transformation. This historic site is just steps away from Wall Street and stands as a testament to New York City's rich architectural history. Once a pinnacle of commerce where every diamond entering the United States was traded, it...

Continue Reading
Innofactor Plc Corrects Transaction Date for CEO Share Transfer

Updated Category News Views 83

Innofactor Plc: Important Update on Managers’ Transactions Innofactor Plc has released an important update concerning its managers’ transactions, particularly focusing on Chief Executive Officer Sami Ensio. This update reflects an amendment in a previous communication regarding the specific execution date of a share transfer. Clarification of Share Transfer Date On a...

Continue Reading
How Passport Is Revolutionizing Parking Management in Cities

Updated Category News Views 229

Transforming Urban Parking: Passport's Role in City Management Passport is leading the charge in innovative parking management technology across bustling cities. As a partner with numerous destination cities, they focus on easing congestion and improving parking efficiency, especially during peak seasons, such as spring break. The Spring Break Surge and Its Challenges...

Continue Reading